|

Gallium (68Ga) Edotreotide PET/CT for Imaging Patients With Gastrointestinal Pancreatic Neuroendocrine Tumors

RECRUITINGPhase 3Sponsored by Jiangsu HengRui Medicine Co., Ltd.
Actively Recruiting
PhasePhase 3
SponsorJiangsu HengRui Medicine Co., Ltd.
Started2024-02-22
Est. completion2025-11-01
Eligibility
Age18 Years – 75 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06091748

Summary

This is a single-arm imaging study using DOTATOC peptide, labelled with the Gallium (68Ga) tracer.

Eligibility

Age: 18 Years – 75 YearsHealthy volunteers accepted
Inclusion Criteria:

1. Able and willing to provide a written informed consent;
2. 18\~75 years old,male or female；
3. ECOG performance status 0 or 1;
4. Confirmed or suspicion of GEP-NET.

Exclusion Criteria:

1. Unable to lie flat for the entire imaging duration (e.g. persistent cough, claustrophobia, severe arthritis, etc.), unable to enter the PET/CT device;
2. Individuals planning to be pregnant, and lactating women;
3. Individuals with concurrent active infections or with unexplained fever \>38.5°C for more than 1 hour during the screening period or prior to administration of investigational medication.

Conditions2

Advanced Gastroenteropancreatic Neuroendocrine TumorCancer

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.